The pop-quiz questions are on unrelated aspects of GLP-1 receptor agonist therapy and the answers may add a new detail or 2 to your knoweldge of the class.
1. What is the effect of GLP-1 receptor agonists on non-alcoholic fatty liver disease (NAFLD)?
A. Improve NAFLD
B. Worsen NAFLD
D. Have no effect on NAFLD
E. The effect on NAFLD has not been studied
1. Ao N, Yang J, Wang X, Du J. Glucagon-like peptide-1 (GLP-1) preserves non-alcoholic fatty liver disease (NAFLD) through inhibition of the endoplasmic reticulum (ER) stress-associated pathway. Hepatol Res. 2015 Jul 4. doi: 10.1111/hepr.12551.
2. Handelsman Y, Bloomgarden Z, Gruneberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015 Executive Summary. Endocr Pract. 2015; 21:413-437.
3. American Diabetes Association. Professional Practice Committee. Standards of Medical Care in Diabetes – 2015. Diabetes Care. 2015;38(Suppl 1):S3. doi: 10.2337/dc15-S00.
4. Davis PN, Ndefo UA, Oliver A, Payton E. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus. Am J Health Syst Pharm. 2015;72:1097-1103. doi: 10.2146/ajhp140260.
5. Tanzeum [package insert]. Research Triangle Park, NJ. GlaxoSmithKline LLC; 2015.